GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (NAS:SGMT) » Definitions » Return-on-Tangible-Asset

Sagimet Biosciences (Sagimet Biosciences) Return-on-Tangible-Asset : -18.21% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sagimet Biosciences's annualized Net Income for the quarter that ended in Mar. 2024 was $-26.52 Mil. Sagimet Biosciences's average total tangible assets for the quarter that ended in Mar. 2024 was $145.62 Mil. Therefore, Sagimet Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -18.21%.

The historical rank and industry rank for Sagimet Biosciences's Return-on-Tangible-Asset or its related term are showing as below:

SGMT' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -127.79   Med: -42.97   Max: -28.38
Current: -31.52

During the past 5 years, Sagimet Biosciences's highest Return-on-Tangible-Asset was -28.38%. The lowest was -127.79%. And the median was -42.97%.

SGMT's Return-on-Tangible-Asset is ranked better than
56.58% of 1550 companies
in the Biotechnology industry
Industry Median: -40.335 vs SGMT: -31.52

Sagimet Biosciences Return-on-Tangible-Asset Historical Data

The historical data trend for Sagimet Biosciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Return-on-Tangible-Asset Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-127.79 -28.38 -38.19 -66.26 -42.97

Sagimet Biosciences Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.41 -111.34 -40.85 -32.66 -18.21

Competitive Comparison of Sagimet Biosciences's Return-on-Tangible-Asset

For the Biotechnology subindustry, Sagimet Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagimet Biosciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Return-on-Tangible-Asset falls into.



Sagimet Biosciences Return-on-Tangible-Asset Calculation

Sagimet Biosciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-27.876/( (33.031+96.719)/ 2 )
=-27.876/64.875
=-42.97 %

Sagimet Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-26.516/( (96.719+194.528)/ 2 )
=-26.516/145.6235
=-18.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Sagimet Biosciences  (NAS:SGMT) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Sagimet Biosciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagimet Biosciences (Sagimet Biosciences) Business Description

Traded in Other Exchanges
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Executives
David Happel director, officer: President & CEO 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Beth C Seidenberg director
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth Rozek officer: General Counsel and CCO SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO CA 94402
George Kemble director SAGIMET BIOSCIENCES INC., 155 BOVET RD., STE. 303, SAN MATEO CA 94402
Jinzi Jason Wu director SAGIMET BIOSCIENCES INC., 155 BOVET RD., SUITE 303, SAN MATEO CA 94402
Dennis Hom officer: Chief Financial Officer C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Kpcb Pbd Associates, Llc 10 percent owner C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Kpcb Pandemic & Bio Defense Fund Llc 10 percent owner 2750 SAND HILL RD, MENLO PARK CA 94025
Eduardo Bruno Martins director 350 CAMBRIDGE AVE, SUITE 350, PALO ALTO CA 94306
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth A Grammer director 78TH FOURTH AVENUE, WALTHAM MA 02451
Anthony M Rimac officer: Chief Operating Officer C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220, EMERYVILLE CA 94608
Patrick J Kerins 10 percent owner